Medical technology company Perimeter Medical Imaging AI Inc (TSXV: PINK) (OTC: PYNKF) reported on Tuesday the completion of patient enrolment in a pivotal study assessing the use of its next-generation Perimeter B-Series OCT system.
The system integrates artificial intelligence (AI) technology with optical coherence tomography (OCT) during breast-conserving surgeries (BCS).
If the study is successful, it will demonstrate a reduction in the number of patients where breast cancer was missed during surgery.
This prospective, multi-centre, randomised, double-arm clinical trial enrolled approximately 530 women, aged 18 years and older, undergoing BCS intended for the treatment of Stage 0-III invasive ductal carcinoma and/or ductal carcinoma in situ. Patients were recruited from 10 clinical sites across the United States and randomised in a 2:1 ratio to the device and control arms. Around 200 of these patients will be used to assess the effectiveness of the Perimeter B-Series, which integrates OCT imaging with the ImgAssist 2.0 AI algorithm, in addressing positive margins as compared to the standard lumpectomy procedure.
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
Viatris reports positive results for EFFEXOR in GAD treatment in Japan
ALK secures U.S. FDA approval for AccuTest Allergy Skin Testing Devices
Conformal Medical reports start of GLACE study
Brain+ launches Ayla CST Assistant following UK regulatory approval
Accelerate Diagnostics receives FDA clearance for automated blood culture system
Photocure's partner Asieris presents Cevira Phase III subgroup analysis at 2024 CSCO Annual Meeting
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Implantica advances RefluxStop with CE mark study results and prepares for FDA submission
Arrowhead Pharmaceuticals seeks approval for ARO-INHBE obesity study